What is the sales price of lorlatinib/lorlatinib in India

Lorlatinib (Lorlatinib) is a third-generation ALK (anaplastic lymphoma kinase) and ROS1 inhibitor that is widely used to treat patients with ALK-positive non-small cell lung cancer and has shown significant efficacy in the treatment of patients who are resistant to first- and second-generation ALK inhibitors. The drug was developed by Pfizer and has been approved for marketing in the United States, Europe and some Asian countries, and has gradually become one of the standard treatment options in clinical practice.

In the Indian market, as there is currently no official generic version of lorlatinib approved for marketing, local pharmaceutical companies in India do not produce this type of drug on a large scale. At the same time, due to the ongoing patent protection, Pfizer has not officially launched the original drug in India, so the Indian market has not yet formed a stable supply chain for lorlatinib. This situation is also common in some developing countries around the world, and it belongs to the stage where the original drug has not yet been commercialized.

However, since India has significant advantages in global medical tourism and generic drug circulation, some international drug procurement channels may assist patients to obtain lorlatinib imported from other countries through third-party platforms, and the price usually varies based on supply sources and exchange rate fluctuations. Compared with the price of tens of thousands of yuan in the European and American markets, even if lorlatinib is obtained through unofficial channels, it still has a certain cost advantage. However, since it is not a drug registered and marketed in India, there may still be problems with legality, quality assurance and drug availability.

Therefore, for patients considering obtaining lorlatinib in India, it is recommended to obtain the drug through cross-border medical services or formal international pharmacy consultation, while ensuring that the source of the drug is traceable, the packaging label is compliant, and the purity of the ingredients is checkable to ensure drug safety. In the absence of Indian generic drugs and original drugs, patients must not trust unauthorized sources of drugs on the market and should use them with caution under the guidance of doctors and pharmaceutical personnel.

References：https://www.lorbrena.com/